Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection

Next Previous
X
Search
Trial Profile

A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Casirivimab/imdevimab (Primary) ; Casirivimab/imdevimab (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 16 Feb 2022 Results assessing Viral Kinetics in Covid-19 Outpatients Treated with Casirivimab+Imdevimab Combination using data from two trials (NCT04425629 and NCT04666441) presented at the 29th Conference on Retroviruses and Opportunistic Infections
    • 05 Nov 2021 According to a Chugai Pharma Europe media release, the Ministry of Health, Labour and Welfare (MHLW) has approved RONAPREVE for the additional indication of the prevention of symptomatic SARS-CoV-2 infection (COVID-19), based on the results from REGN-COV 206,REGN-COV 20145 and JV43180 studies. The Special Approval for Emergency under article 14-3 of the Pharmaceuticals and Medical Devices Act was applied to this approval

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top